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Summary
Skin irradiation with ultraviolet B (UVB) is a common and often durable treatment for psoria-
sis and other inflammatory skin disorders. We studied the effects ofUVB on keratinocytes and
leukocytes in psoriatic tissue and in culture. In nine patients treated repetitively, most of the
cellular and molecular changes that typify the psoriatic epidermis reverted to normal. Kerati-
nocyte hyperplasia, assessed by expression of the Ki-67 cell cycle antigen, decreased by 70%,
and residual cell proliferation was appropriately confined to the basal layer. Epidermal thicken-
ing was reduced by 60%, and a granular layer reformed. Expression of keratin 16, as well as su-
prabasal integrin cx3 and insulin-like growth factor-1 receptors, was eliminated, whereas filag-
grin increased markedly. UVB also depleted >90% of the CD3+, CD8+, and CD25+ T cells
from the psoriatic epidermis, whereas dermal T cells were only minimally depressed. The latter
finding parallels the known inability of these doses of UVB to penetrate the dermis. In tissue
culture, UVB was antiproliferative and cytotoxic toward T cells and keratinocytes, but the T
cells were 10-fold more sensitive. Furthermore, low doses of UVB induced apoptosis in lym-
phocytes but not keratinocytes, as detected by the TUNEL (TdT-mediated dUTP-biotin nick
end labeling) technique. The selective effects of UVB on intraepidermal T cells in situ and in
culture support the hypothesis that epidermal alterations in psoriasis can be normalized by a de-
pletion of activated intraepidermal T cells.
P
soriasis is a common skin disorder typified by hyperpla-
sia and incomplete differentiation of epidermal kerati-
nocytes . These epidermal changes parallel those seen in
wound healing and are collectively termed the "regenera-
tive phenotype ." Molecular markers of this phenotype in-
clude the synthesis of such keratinocyte products as the ~j-3
protein and keratins 6 and 16, suprabasal expression ofinte-
grin 0 and IGF receptors, and reduced levels of the filag-
grin and involucrin proteins that mediate keratin cross-
linking and stratum corneum formation (1-3 and Gottlieb,
S. L., E . Hayes, P. Gilleaudeau, I. Cardinale, A. B. Gottlieb,
andJ. G. Krueger, manuscript submitted for publication).
Psoriasis is also accompanied by an infiltration of acti-
vated T cells. CD25+ and CD3+ cells are found in both the
epidermis and dermis, the former being predominantly
CD8+ and the latter CD4+ (4-6) . Both types of T cells
have been proposed to play a pathogenic role (6, 7) . A role
for CD8+ cells is favored by the observed linkage of psoria-
sis to certain MHC I alleles, especially HLA Cw6 (8), and
the skewing of CD8+ TCR V(3 usage to the VP 3 and 13 .1
subtypes (9) . Other inflammatory dermatoses are not ac-
companied by a high density of CD8+ T cells, especially
activated CD25 + cells in the epidermis (10) .
Aberrant keratinocyte proliferation, regenerative epider-
mal differentiation, and infiltration ofCD8+ T cells in pso-
riatic epidermis were recently shown to be sensitive to a
new therapeutic modality, the IL-2 diphtheria toxin conju-
gate DAB389 IL-2 (11) . Since IL-2 directs the toxin to acti-
vated immune cells rather than to keratinocytes, a patho-
genic role for T cells is indicated. The reciprocal also applies,
i.e., psoriatic epidermal changes are only partly reversed by
treatments (e.g., calcitriol, etretinate, or cyclosporine) that
produce lesser reductions in infiltrating epidermal T cells
(12, 13 and Lu, L, P. Gilleaudeau, J. A. McLane, N. Heftler,
M. Kamber, S. Gottlieb, J. G. Krueger, and A. B. Gottlieb,
manuscript submitted for publication) .
Skin irradiation with ultraviolet light in the 280-320-nm
range (ultraviolet B or UVB)' is one of the most common
treatments for extensive psoriasis and can produce long-
lived clinical remissions. UVB can be immunosuppressive,
possibly at the level of antigen-presenting dendritic cells
(14, 15) . UVB also has direct effects on T cells, including
'Abbreviations used in this paper: MED, minimum erythema dose; PUVA,
psoralen + UVA; TUNEL, TdT-mediated dUTP-biotin nick endlabel-
ing; UVB, ultraviolet B.
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and direct cytotoxicity (14-17). These UVB effects have
been previously studied, chiefly in the context of the sensi-
tization phase ofthe immune response. Much less informa-
tion is available on the ability ofUVB to modulate ongoing
lymphocyte function in chronic disorders, especially in a
human disease like psoriasis.
Here we describe findings on the effects of repetitive
UVB therapy in nine consecutive patients with extensive
psoriasis. UVB normalized a large group of cellular and
molecular disease markers, but primarily reversed the infil-
trate of epidermal, rather than dermal, T cells. Additional
tissue culture studies showed that UVB, in doses that might
be expected to penetrate the epidermis, inhibited prolifera-
tion and induced cytotoxicity or apoptosis in T cells to a
much greater degree than it did in keratinocytes. Coupling
our results with earlier data showing that the epidermal pa-
thology of psoriasis can be reversed by an IL-2 toxin, we
conclude that UVB exerts its therapeutic effects principally
at the level of activated epidermal T cells.
Materials and Methods
UVB Treatment andMeasurement.
￿
Patients with extensive pso-
riasis (>10% body surface area affected) were hospitalized for in-
patient UVB treatment on a modified "Goeckerman" protocol.
Upon entry into the study, the patients had not been treated with
systemic antipsoriatic medications for a minimum of 4 wk and
had not been treated with topicalagents for a minimum of2 wk.
For each patient, a minimum erythema dose (MED) was estab-
lished before whole body irradiation, which was begun with a
UVB dose 10-20% lower than the MED. For each subsequent
day, the UVB dose was increasedby 10% unless marked erythema
developed. Treatment was terminated upon attaining clinical res-
olution of psoriatic lesions, typically after 4-5 wk of daily treat-
ment. (4 of 13 patients sequentially enteredinto this studydidnot
respond to UVB treatment, and posttreatment effects were not
studied in these nonresponders.) UVB treatment was given in
conjunction with skin lubrication using petrolatum containing
3% crude coal tar, but the tar-containing preparation was re-
moved from the skin before each irradiation. Skin was irradiated
in a unit (model 57000; Psoralite Corp., Columbia, SC) contain-
ing LS-FS72T12-UVB-HO fluorescent bulbs, which emit in a
broad peak of285-345 nm except for a spike of increased irradi-
ance at 313 nm. UVB output was metered with a radiometer
(model 11,1700; International Light, Newburyport, MA) andcali-
brated UVB detector (model SED 240; InternationalLight). Irra-
diation of cultured cells was performed using a panel of smaller
(24 in.) fluorescent bulbs with identical spectral output and me-
tering with the same UVB detector.
Histopathological Assessment.
￿
6-ltm Cryostat sections were made
on biopsies of unaffected skin and oflesional psoriatic skin taken
immediately before the start of UVB treatment and again upon
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completion. Allmethods have been described (5). Briefly, immu-
nohistochemical staining of tissue was performed as described (5)
using 3-amino-9-ethylcarbazol as the chromagen, since its red re-
action product could easily be distinguishedfrom melanin. Mouse
mAbs to a3-integrin were a gift from Dr. Anthony Albino (Me-
morial Sloan-Kettering Cancer Center, NewYork). Mouse mAbs
to ICAM-1, clone RR1/1, were as previously described (18).
Epidermal thickness was measured with a calibrated microscope
ocular (5). Hematoxylin and eosin-stained tissue sections were
prepared by a commercial laboratory from formalin-fixed, paraf-
fin-embedded tissue.
Cell Culture Analysis.
￿
Keratinocytes were cultured from neo-
natal human skin using serum-free keratinocyte growth medium
(Clonetics Corp., San Diego, CA) (5). Peripheral bloodmononu-
clear cells were cultured in PHA-containing RPMI 1640 me-
dium (5). A transformed T lymphocyte cell line (HUT 102) was
maintained in RPMI 1640 medium containing 10% FCS. For
UVB irradiation, cells were briefly switched to PBS andwere ir-
radiated in open-topped tissue culture plates, followed by re-
placement with the usual growth medium. Keratinocyte prolifer-
ation was measured by direct cell counting, and lymphocyte
proliferation was determined by the incorporation of [3H]thymi-
dine (5). Assessment ofcell viability was performedby incubating
cells for 90 min at room temperature in buffered saline containing a
mixture oftmM calceinAM (viable cells) and 4 mM ethidium ho-
modimer (dead cells) (both dyes were obtained from Molecular
Probes, Inc., Eugene, OR). Fluorescence of calcein or ethidium
was visualized using a Photon icroscope III (Carl Zeiss, Inc.,
Thomwood, NY) equipped with excitation and barrier filters for
green and red fluorescence. Induction ofDNA fragmentation or
apoptosis was detected by the TUNEL (TdT-mediated dUTP-
biotin nick endlabeling) reaction as described (21). The TUNEL
procedure was modified to include a 30-min wash with 0.01 SSC
buffer and a briefwash with 10X Tris-buffered saline (pH 7.6) af-
ter incubation ofcells with biotin-dUTP (Boehringer Mannheim
Biochemicals, Indianapolis, IN) andTdT enzyme (Promega, Mad-
ison, WI). Controls included reactions in which TdT was omit-
ted. Positive staining reactions were confirmed with a second de-
tection system (digoxigenin-conjugated dUTP followed by
peroxidase-conjugated sheep antidigoxigenin antibodies).
Results
The effects of phototherapy on epidermal and immuno-
logical activation in lesional psoriatic plaques were studied
in nine patients, who responded to this form of therapy by
clinical clearing of psoriatic lesions. For consistent delivery
of phototherapy, all patients were treated as inpatients in
our General Clinical Research Center and were closelyob-
served for daily application of topical tar ointment and for
development ofphototoxicity on therapy. Increasing (sub-
erythogenic) doses of UVB were delivered each day for an
average treatment of 27 d (the cumulative exposure to
UVB averaged 4.7 J/cm2 per patient, which is equivalent
Figure 1.
￿
Pathological and immunohistochemical assessment ofpsoriatic epidermis before and after UVB treatment. The left column displays micro-
graphs from untreated psoriasis, whereas the right column shows paired micrographs from UVB-treated psoriasis. Sections have been hematoxylin and
eosinstained (A and B) or reactedwith antibodies to the Ki67 nuclearprotein (C and D), to filaggrin (E and F), to keratin 16 (G andH), or to a3-inte-
grin (I andj). In (A and B), "i"points to chronic inflammatory dermal cellsand"g" points to agranular layer; in (C and D), arrows pointto some Ki67-
positive nuclei; in (E), arrows point to focalareasofepidermis expressing filaggrin; in (I), arrows point to suprabasal keratinocytes expressing cell surface
a3-integrin. All micrographs are shown at the same magnification (X80).Figure 2 .
￿
Quantitative analysis of epidermal acanthosis or keratinocyte
Ki67 reactivity in psoriatic skin before and after UVB treatment. (A) Bar
graphs show mean epidermal thickness for psoriatic lesional and unaf-
fected skin in patients before and afterUVB treatment (standard error is
shown for each mean) . P values for differences between untreated and
UVB-treated epidermis were either P<0.001 (***), P<0.05 (*), or P>
0.05 (ns) . (B) The number of Ki67+ nuclei per microscope field for le-
sional psoriatic epidermis before and afterUVB treatment is shown for in-
dividual patients . Solid bars indicate mean values for each group .
to a mean dose of 174 mJ/cm2 per d) . Upon the conclusion
of treatment, psoriatic plaques were converted to flat, hy-
perpigmented patches without residual scale or erythema in
skin areas exposed to phototherapy . Markers ofcellular ac-
tivation in the epidermis and infiltrating leukocytes were
studied in skin biopsies obtained from lesional plaques at
the conclusion of phototherapy, and the findings were
compared to biopsies obtained from psoriatic lesions imme-
diately before starting phototherapy .
Effects of Phototherapy on Epidermal Pathology .
￿
Psoriatic
pathology is largely defined by a series of changes in the
proliferation and differentiation characteristics of epidermal
keratinocytes . In comparison with normal skin (or unaf-
fected skin in psoriatics), lesional psoriasis is characterized
by marked keratinocyte hyperplasia, by profound thicken-
ing of the epidermis (acanthosis), by incomplete terminal
differentiation of keratinocytes (absent granular layer and
nuclear retention in cornified epidermis [parakeratosis]), and
by parakeratosis, an "alternate" or "regenerative" differen-
tiation program that alters expression of epidermal proteins
and cytokines (1, 2) . A number of inflammatory alterations,
considered below, also occur in active psoriatic lesions.
Upon the conclusion of phototherapy, as illustrated in
Fig . 1, A and B, lesional psoriatic epidermis had markedly
reduced acanthosis, a granular layer was typically restored
and parakeratosis in the stratum corneum was resolved, al-
though this layer was thicker than normal (Fig . 1 D) . Nu-
clear retention (parakeratosis) was not observed in the stra-
tum corneum of psoriatic lesions after phototherapy . Of
note, however, were numerous mononuclear inflammatory
cells that continued to be present in the dermis ofUVB-
treated psoriatic lesions (Fig . 1 B) . Keratinocyte prolifera-
tion, as judged by expression of the Ki67 nuclear protein
confined in cycling cells, was markedly reduced such that
residual proliferating keratinocytes were confined to the
basal layer (compare Fig . 1, C and D) as in normal skin . Fil-
aggrin, a protein normally produced by keratinocytes un-
dergoing terminal differentiation in the granular layer, was
minimally expressed by lesional epidermis (Fig. 1 E) but
highly expressed by psoriatic keratinocytes following UVB
treatment (Fig . 1 F) . Because a visible granular layer is pro-
duced by the action of filaggrin to aggregate keratin fila-
ments, the restored granular layer after phototherapy prob-
ably results from increased production of filaggrin by
differentiating keratinocytes .
Fig . 2 presents quantitative analyses of these changes .
The thickness of the epidermis was quantified separately for
viable layers (stratum Malpighi) and cornified layers . Pho-
totherapy reduced epidermal thickness by 60%, with re-
ductions evident in both the stratum Malpighi and the stra-
tum corneum (P <0 .001) . We noted that epidermal
thickness of nonlesional skin was somewhat greater after
phototherapy (101 versus 137 gym, P = 0.07) and that a
statistically significant increase in thickness of the statum
corneum (25 versus 37 [,m, P = 0.03) also could be mea-
sured (Fig . 2 A) . The stratum corneum of treated plaques
(Fig . 1 D), as well as the unaffected epidermis (not shown),
appeared visibly thicker than unaffected skin before photo-
therapy . Keratinocyte proliferation was also consistently re-
duced by phototherapy, with an average reduction of69%
(P <0.001) (Fig . 2 B) .
Regenerative differentiation of the epidermis is the term
used to describe a transient phenotype associated with a
Figure 3 .
￿
Immunohistochemical assessment ofT lymphocyte infiltration and inflammatory activation in psoriatic skin before and afterUVB treatment .
The left column displays micrographs from untreated psoriasis, while the right column shows paired micrographs from UVB-treated psoriasis . Cryostat
skin sections have been reacted with antibodies to CD8 (A and B), toCD4 (C and D), toCD1 (E and F), to HLA-DR (G and H) or to ICAM-1 (I and
J) . In (A), arrows identify CD8+ cells in epidermis; in (G), arrows point to keratinocytes expressing HLA-DR ; in (I), arrows point to keratinocytes ex-
pressing ICAM-1 ; in (I) and (J), ICAM-1 expression by vascular endothelium is indicated by v.
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consistently displays this phenotype, which is marked by al-
tered expression of keratin 16, a3-integrin, IGF-1 recep-
tors, and the differentiation-associated proteins involucrin
and filaggrin (2, 20, 21) . In nine out of nine cases, we ob-
served that UVB reversed the regenerative epidermal
growth . Keratin 16, for example, was expressed by supra-
basal keratinocytes in all psoriatic lesions before treatment
(Fig . 1 G), and it was absent from lesional epidermis after
phototherapy (Fig . 1 H) . a3-Integrin was expressed in le-
sional epidermis (Fig . 1 I) by both basal and suprabasal ke-
ratinocytes, but after phototherapy (Fig . 1 J) its expression
was predominantly basal, as in normal epidermis. Expres-
sion of involucrin and of IGF-1 receptors was also normal-
ized to the suprabasal and basal layers, respectively (not
shown) . In sum, all the known changes in the regenerative
epidermal growth pattern were coordinately reduced by
phototherapy of active psoriatic plaques .
Effects of Phototherapy on Tissue Infiltration by T Lymphocyte
Subsets . The appearance ofCD8+ , CD4 + , and CD1+ cells
in lesional psoriatic tissue before and after phototherapy is
illustrated in Fig . 3 . These micrographs illustrate numerous
CD8+ lymphocytes in diseased epidermis and dermis be-
fore treatment (Fig. 3 A) but only a marked reduction of
CD8+ lymphocytes in the epidermis after phototherapy
(Fig . 3 B) . CD4+ cells were common in the reticular der-
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mis and in the papillary dermis, near the dermal-epidermal
interface in lesional skin (Fig. 3 C) . Some reduction in
CD4+ cells was evident in the epidermal-dermal interface
and in the upper papillary dermis after UVB treatment (Fig .
3 D) . Fig. 4 presents a quantitative summary ofT lympho-
cytes infiltrating the epidermis and dermis of lesional psori-
atic tissue before and after phototherapy . As in earlier stud-
ies (4, 5), the T lymphocytes infiltrating the epidermis were
predominantly CD8+ , whereas those infiltrating the dermis
were chiefly ofthe CD4+ phenotype (Fig. 4) . Total (CD3+ )
T cells in the epidermis were reduced by an average of91%
(11-fold) by phototherapy (P <0.001), whereas these cells
were reduced by a mean of only 19% (1 .2-fold) in the der-
mis . The major T cell subset responding to phototherapy in
the epidermis was CD8+, showing a mean reduction of
85% (P <0.001), whereas CD4+ cells were reduced by
49% (P <0.01) . Expression of the IL-2 receptor a chain
(CD25) was reduced to an even greater extent than was ex-
pression ofT cells in the epidermis, with a mean reduction
of95% (21-fold, P <0.001) . In the dermis, a 36% reduc-
tion in CD4+ cells and a 37% reduction in CD25+ cells
were measured (Fig. 4) . Interestingly, epidermal CD1+
(Langerhans) cells did not appear to be depleted, and even
may have been increased, in epidermis of psoriatic lesions
after phototherapy (Fig . 3, E and F) . Although Langerhans
cells were not strictly quantified after CD1 staining, neither
CD8 CD4 CD25
I r -1
40 50 60 70 80 90
Reduction in Epidermal Thickness (%)
Figure 4.
￿
Quantitative analysis
of T cell infiltration in psoriatic
lesional tissue before and after
UVB treatment. Top panels
show mean numbers of CD3+ ,
CD8+ , CD4+, or CD25` cells in
the epidermis or dermis ofpsori-
atic lesional tissue before treat-
ment (solid bars) or after UVB
treatment (hatched bars) ; standard
error is shown for each mean
value . P values for differences
between untreated and UVB-
treated tissue were P <0.001
(***), P <0.01 (**), P <0.05
(*), or P >0.05 (ns) . Bottom
panels display the relationship
between reduction in epidermal
acanthosis (thickness) and reduc-
tion in the number of total T
lymphocytes (CD3+) in either
the epidermis or dermis of biop-
sies analyzed for individual pa-
tients .psoriatic lesional epidermis nor unaffected epidermis showed
marked reductions in Langerhans cells at the conclusion of
UVB treatment. In fact, the distribution of bone marrow-
derived cells in psoriatic epidermis after phototherapy (few
T lymphocytes, numerous Langerhans cells) is similar to
that observed in normal skin or the unaffected skin of pso-
riatics. The presence of numerous residual T lymphocytes
in psoriatic lesional skin after phototherapy, however, con-
trasts sharply with unaffected or normal skin, both ofwhich
contain only scant T lymphocytes outside the vasculature (5).
To illustrate further the relationship between epidermal
activation and epidermal T cells, the lower panels of Fig. 4
graph the relationships between the reduction in epidermal
or dermal CD3+ cells and the reduction in epidermal acan-
thosis produced by phototherapy. In individual cases, pho-
totherapy reductions in epidermal thickness range from 43
to 80%, and reductions in epidermal CD3+ T cells range
from 70 to 100%. The correlation coefficient of these re-
ductions was 0 .69 in relation to the magnitude in reduction
of epidermal CD3+ cells (Fig. 4, lower left) . In contrast, der-
mal CD3+ cells were reduced by a maximum of 58% or in-
creased by up to 20% in individual cases, and these changes
were poorly related to reductions in epidermal thickness
(r = 0.18; Fig. 4, lower right) .
The effect of phototherapy on expression of HLA-DR
and ICAM-1 by keratinocytes in lesional psoriasis was also
examined (Fig. 3, G-J) . Although both of these proteins
were produced by keratinocytes in active lesions (Fig. 3, G
and I), little or no expression could be detected after pho-
totherapy (Fig. 3, H andj). HLA-DR continued to be ex-
pressed by Langerhans cells in the epidermis after treatment
(Fig. 3 H), and ICAM-1 was still produced by endothelium
ofpapillary blood vessels and other dermal cells (Fig. 3J).
Effects of UVB on Keratinocytes and Lymphocytes In Vitro.
To distinguish among the possible cellular targets of photo-
therapy, we compared the ability of UVB to directly sup-
press the growth ofkeratinocytes and leukocytes. We used
the same broad-band UVB fluorescent source (bulbs emit
radiation over a broad band from 285 to 345 nm, with a
sharp peak at 313 nm) with identical metering of output
intensity. Cells were mock-irradiated or treated with 1-20
mJ/cm2 UVB, and proliferation was measured after 1, 2, 3,
or 4 d. Keratinocyte growth was minimally inhibited by 4
mJ/cm2 , moderately inhibited by 8-12 mJ/cmz, and com-
pletely inhibited by 16-20 mJ/cmz (Fig. 5 A). In PHA-
activated peripheral blood mononuclear leukocytes, 2 mJ/
cm2 of UVB produced detectable inhibition of lymphocyte
growth 1-2 d after exposure, 4 mJ/cm2 produced 65% in-
hibition 3 d after exposure, and complete inhibition was
produced by -_8 mJ/cmz (Fig. 5 B) . A transformed T-lym-
phocyte cell line (HUT 102) was similarly sensitive to the
antiproliferative effects ofUVB (Fig. 5 C). Thus, lympho-
cytes appeared more sensitive than keratinocytes to the an-
tiproliferative effects of UVB irradiation.
The inhibition of proliferation in lymphocytes and kera-
tinocytes was associated with increased cellular cytotoxicity
as assessed by fluorescent probes that distinguish viable
from nonviable cells (Fig. 6) . This assay scores for live cells
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￿
Comparative study of antiproliferative effects o£UVB in hu-
man keratinocytes or PBMC in vitro. (A) Keratinocytes grown in serum-
free medium were irradiated with 0-20 mJ/cmz UVB, and cell growth
was assessed after 1, 2, 3, or 4 d by counting of cell numbers. Mitogen-
activated PBMC (B) or HUT 102 cells (C) were exposed to 0-20 mJ/
cm2 UVB, and cell proliferation was assessed after 1, 2, or 3 d by [H]thy-
midine incorporation. Values are graphed for exposure to 1-20 mJ/cm2
in relationship to mock irradiated cultures. Legends to the right of each
figure define symbols for different levels ofUVB exposure.
by uptake of calceinAM (nonfluorescent substrate), which
is converted by cellular esterases to calcein which emits green
fluorescence. Conversely, esterase-negative cells with com-
promised plasma membranes (nonviable) do not cleave cal-
ceinAM but will allow ethidium homodimer to enter, and
this is detected as red nuclear fluorescence. Hence, everyFigure 6 .
￿
Comparative study of cytotoxic effects ofUVB inhuman keratinocytes or leukocytes in vitro . Micrographs are shown for PBMC (A-C) or
keratinocytes (D-F) after incubation ofcells in calceinAM (substrate for green fluorescence, live cells) and ethidium dimer (red fluorescence, dead cells) .
Lymphocytes were mock irradiated and examined after 72 h in culture (A), or they were irradiated with 8 mJ/cm2 and examined after24 (B) or 72 h (C) .
Keratinocytes were examined 72 h after irradiation with 16 (D) or 64 mJ/cm2 (E and F) . Micrographs for Eand Fshow the same field of cells photo-
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viability. Exposure of lymphocytes to 8 mJ/cm2 of UVB
led to massive cell death (>90% nonviable cells) 3 d after
UVB exposure (Fig. 6, A-C). Lethality was not immedi-
ately evident, since lymphocytes were fully viable 1 d after
exposure to 8 mJ/cm2 UVB . Exposure oflymphocytes to 4
mJ/cm2 produced -50% cell death at 3 d using this assay,
whereas exposure to 2 mJ/cm2 produced <20% cell death.
In contrast, keratinocytes were more resistant to the cyto-
toxic effects of UVB. 3 d after exposure to 8 or 16 mJ/cm2,
keratinocytes appeared fully viable (Fig. 6 D) . Exposure to
64 mJ/cm2 produced death in -50% of keratinocytes (Fig.
6, E-F), a level of cytotoxicity produced in lymphocytes
after exposure to only 4 mJ/cm2 of UVB. Keratinocytes
treated with 64 mJ/cm2 showed cytoplasmic blebbing
characteristic of apoptosis (22).
To explore further the ability ofUVB to induce apopto-
sis in lymphocytes or keratinocytes, cells that had been UVB
treated were examined for DNA fragmentation by the
TUNEL procedure. Transformed lymphocytes or PBMC
exposed to 8 mJ/cm2 UVB showed clear TUNEL positiv-
ity 24-48 h after UVB treatment. Fig. 6 H illustrates
TUNEL positivity in both intact nuclei (arrows) and in nu-
clear fragments (open arrows), which are morphological indi-
cators of advanced apoptosis. As a control for the TUNEL
reaction, Fig. 6 G shows absence of nuclear staining in
UVB-treated lymphocytes when only TdT enzyme was
omitted from the reaction. In contrast to the lymphocyte
results, no significant TUNEL reactivity was detected in
cultured keratinocytes 1-3 d after exposure to 1-16/cm2
mJ UVB (Fig. 6 1), but some TUNEL-positive cells could
be detected after exposure to 64 mJ/cm2 (not shown) .
Thus, TUNEL reactivity paralleled viability measurements
made in keratinocytes with calcein/ethidium uptake. Both
viability and TUNEL reactions indicate greater lethality of
UVB in lymphocytes than in epidermal keratinocytes, and
the TUNEL reactions suggest that apoptosis is induced in
lymphocytes after exposure to relativelylow levels ofUVB.
Discussion
One of the most common treatments for moderately se-
vere psoriasis is skin irradiation with UVB, often given af-
ter skin lubrication with tar-containing emollients. A num-
ber of earlier studies have demonstrated effects of UVB on
normal skin that are paradoxical in relationship to therapeu-
tic improvements. In normal skin, UVB increases TGF-a
synthesis by keratinocytes, accelerates keratinocyte prolifer-
ation, and increases overall epidermal thickness (23-25).
Several cytokines thought to initiate or enhance psoriatic
pathology are also increased after UVB irradiation of skin
or cultured keratinocytes: IFN-y (25), TNF-ot (20, 26),
IL-1 (27), IL-6 (28) and IL-8 (29). Furthermore, UVB irra-
diation increases leukocytic infiltration (30) and activates
neutrophil effector functions (31) . Therefore, it might be
anticipated that UVB treatment of psoriatic skin would
worsen hyperplasia and inflammation in lesions, but the en-
tirely opposite effect was observed. We observed reduced
epidermal thickness, diminished keratinocyte proliferation,
decreased abundance of immunoreactive IL-6 in lesional
tissue (32), and virtual elimination of interferon--y-induced
proteins (HLA-DR and ICAM-1) in psoriatic keratinocytes.
In effect, UVB treatment reversed the hyperplasia and re-
generative growth to levels associated with normal skin, even
though existing evidence predicted the opposite.
One explanation for this paradox is that UVB may oper-
ate primarily on T lymphocytes in psoriatic tissue. In fact,
UVB treatment produced consistent and profound deple-
tion ofT lymphocytes from psoriatic epidermis. T cell acti-
vation appeared to be decreased even further, as judged by
expression of the IL-2 receptor oc chain (CD25) . Dermal
lymphocytes were much less affected by UVB treatment.
Our observations clearly oppose the view that therapy-
related improvements are mediated by increased numbers
of epidermal lymphocytes (33) .
As used therapeutically, 5-10% of incident radiation in
the UVB spectrum should penetrate the epidermis to the
basal layer (the remaining energy is scattered at the epider-
mal surface or is absorbed by keratinocyte proteins or other
molecules) (34). Our psoriatics were treated on a daily basis
with UVB averaging 174 mJ/cm2. Thus, at the midpoint of
therapy, one would expect an average penetration of8-17
mJ/cm2 to the basal layer. UVB penetration beyond the basal
layer would be rapidly attenuated by the dermal-epidermal
interface and upper dermis (34). Irradiation of transformed
lymphocytes or mitogen-activated PBMC with 4-8 mJ/
cm2 of UVB in vitro immediately inhibited proliferation
and then induced apoptotic cell death over a somewhat
longer time frame. Thus, the expected delivery of UVB to
psoriatic epidermis near the midpoint of therapy approxi-
mates the energy levels sufficient to kill activated lympho-
cytes. The minimal penetration of UVB into dermal tissue
is then the most logical explanation for the minimal effects
of UVB observed on dermal lymphocytes. In contrast, ke-
ratinocytes appear to be relatively resistant to the cytotoxic
effects of UVB, since UVB was cytotoxic for keratinocytes
at levels that were at least 10-fold higher than those for
lymphocytes. The deletion of activated lymphocyte clones
from psoriatic tissue might then explain the "remittive" na-
ture of UVB treatment, i.e., its ability to produce sustained
therapeutic improvement, whereas noncytotoxic immuno-
suppressive agents, e.g., corticosteroids or cyclosporine, do
not produce this sustained therapeutic benefit (5).
UVB might also exert immunosuppressive actions inde-
graphed with barrier filters for green or red fluorescence, and arrows point to identical areas of the microscopic field. Bar in C = 10 wm. In GI,
TUNEL reactions were run on HUT 102 cells (G and H) 2 d after exposure to 8 mJ/cm2 UVB or on keratinocytes (n after exposure to 16 mJ/cm2
UVB. (H) Solid arrows point to labeled intact nuclei and open arrows point to labeled nuclear fragments. TdT was omitted from the reaction shown in
G as a control.
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In human skin, direct UVB irradiation ablates or reduces
contact hypersensitivity to a number of antigens (14, 15,
35) . In various systems, UVB depletes Langerhans cells
from the epidermis, decreases the activation capability of
residual Langerhans cells, and decreases the ability of
Langerhans cells to present viral antigens to lymphocytes
(15, 35-39) . UVB also alters tyrosine phosphorylation of T
lymphocyte proteins, inhibiting T cell activation but not
directly inducing cytotoxicity (40) . UVB also increases syn-
thesis of cis-uroconic acid, IL-10, the IL-1 receptor antago-
nist, and TGF-(3, which are all potentially immunosuppres-
sive mediators (14, 41, 42) . Thus CD25 expression in
UVB-treated psoriatic epidermis, which is reduced overall
more than are T cells, might be modulated via decreased
antigen-APC interactions or by chemical mediators. The
number of Langerhans cells in UVB-treated skin, however,
did not appear to be reduced by repetitive UVB exposures
(Fig. 4 F), an observation that suggests that UVB selectively
affects the T lymphocytes that infiltrate psoriatic epidermis.
The apparently minimal effects of UVB on Langerhans cells
might reflect theirrelative resistance to suberythrogenic UVB
levels. It is possible, however, that continued trafficking of
Langerhans cells into the epidermis might replace those cells
damaged by repetitive UVB exposure.
Intensive UVB treatment of psoriasis leads to relatively
durable clinical remission (5, 43) . Our data establish that a
major cellular correlate of this outcome is the elimination
of intraepidermal lymphocytes and restoration of a normal
growth/differentiation sequence in the epidemis. Psoralen +
UVA (PUVA) treatment has similar effects on the elimina-
tion of epidermal T lymphocytes, the reversal of regenera-
tive epidermal growth, and clinical remissions (5). These
data, when considered with effects produced by DAB319IL-2
and other more selective antilymphocyte agents (11), sug-
gest that disease-mediating lymphocytes reside primarily in
the epidermis or at the dermal-epidermal interface, where
T cells could exert direct effects on epidermal keratinocytes.
The predominant epidermal lymphocytes are CD8+, and a
recent report indicates that these CD8 cells contain only a
limited number of clones (9) . The association o£ MHC
class I alleles with disease susceptibility, the selective accu-
mulation of CD8 + lymphocytes in the epidermis, and
clonality in CD8+, but not CD4+ cells (9), imply that spe-
cific immune activation is MHC class I restricted in psoria-
sis. Epidermal cells could be important targets of effector
CD8+ cells. Keratinocyte injury produced by CTLs in the
epidermis might trigger these cells into a repair or regener-
ative program, or, alternatively, cytokines elaborated by ac-
tivated CD8+ lymphocytes might directly stimulate kerati-
nocyte proliferation (44) . Some cytokines that are elevated
in psoriatic lesions, e.g., IL-2, IL-6, and IFN-y, may pro-
mote efficient maturation of immature CD8+ lymphocytes
into effector CTLs (45, 46), and IFN-y can enhance CD8+-
mediated injury to keratinocytes by modulating MHC class
I expression (47).
Although either CD4+ or CD8+ lymphocytes could
elaborate disease-associated cytokines, the majority of CD4+
clones isolated from psoriatic lesions elaborate cytokines
that suppress keratinocyte proliferation (44) . The patho-
genic significance of CD4+ lymphocytes in psoriatic tissue
is thus somewhat uncertain. CD4+ lymphocytes are fre-
quently abundant in MHC class I-restricted inflammatory
tissue reactions mediated by effector CD8+ lymphocytes
(48). For example, in cutaneous GVH reactions, many
CD8+ effector lymphocytes are localized in the epidermis
(49), but the majority of dermal lymphocytes are CD4+
(50), as in psoriatic tissue. Since the CD4+ lymphocytes
that have been analyzed from psoriatic lesions display no
preferential TCR usage (9), infiltration by this cell type,
though quantitatively dominant in the dermis, may reflect
nonspecific recruitment by inflammatory cytokines and al-
tered vascular adhesion molecules (51). Furthermore, since
most dermal T lymphocytes persist in psoriatic dermis after
UVB treatment, it appears that these cells are not immedi-
ately pathogenic. In fact, the most direct explanation for
the prolonged clinical remissions that are obtained with
UVB or PUVA therapies is that probably through cyto-
toxic actions, these modalities produce profound depletion
of effector lymphocytes residing at the dermal-epidermal
interface or in the epidermis (5). Longer periods of clinical
remission attained by PUVA treatment might be best ex-
plained by the treatment's ability to deplete more dermal
lymphocytes from psoriatic skin than UVB treatment does
(5). In turn, these findings suggest a rational basis for use of
specific immune-modulating agents to treat psoriasis and to
potentially decrease inadvertent toxicity-associated effects
on epidermal keratinocytes.
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